Provided by Tiger Fintech (Singapore) Pte. Ltd.

MoonLake Immunotherapeutics

39.04
-0.3800-0.96%
Volume:182.02K
Turnover:7.19M
Market Cap:2.47B
PE:-20.64
High:40.34
Open:39.90
Low:38.79
Close:39.42
Loading ...

MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update

THOMSON REUTERS
·
26 Feb

MoonLake Immunotherapeutics FY EPS USD -1.89

THOMSON REUTERS
·
26 Feb

MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update

GlobeNewswire
·
26 Feb

Is MoonLake Immunotherapeutics (MLTX) An Oversold Biotech Stock to Buy Now?

Insider Monkey
·
25 Feb

MoonLake Immunotherapeutics (MLTX): the Most Oversold Pharma Stock to Buy According to Analysts

Insider Monkey
·
24 Feb

Pre-Bell|U.S. Futures Extend Gains; MicroStrategy Gains 5%; JD.com Jumps 6%; Nukkleus Soars 60%

Tiger Newspress
·
17 Jan

Goldman Sachs Upgrades MoonLake Immunotherapeutics to Buy From Neutral, Adjusts Price Target to $82 From $62

MT Newswires Live
·
17 Jan

MoonLake Immunotherap Raised to Buy From Neutral by Goldman Sachs

Dow Jones
·
17 Jan

Positive Outlook for MoonLake Immunotherapeutics: Buy Rating Driven by Promising Trial Results and Strategic Consistency

TIPRANKS
·
17 Jan

MoonLake Immunotherapeutics upgraded to Buy from Neutral at Goldman Sachs

TIPRANKS
·
17 Jan

MoonLake Immunotherap Price Target Maintained With a $100.00/Share by HC Wainwright & Co.

Dow Jones
·
10 Jan

MoonLake Immunotherapeutics: Strategic Expansion in Clinical Trials Positions Sonelokimab for Market Growth

TIPRANKS
·
10 Jan

BTIG Adjusts MoonLake Immunotherapeutics' Price Target to $81 From $71, Keeps Buy Rating

MT Newswires Live
·
09 Jan

MoonLake Immunotherapeutics price target raised to $81 from $71 at BTIG

TIPRANKS
·
09 Jan

Analysts Have Conflicting Sentiments on These Healthcare Companies: MoonLake Immunotherapeutics (MLTX) and Accolade (ACCD)

TIPRANKS
·
09 Jan

MoonLake Immunotherapeutics : Btig Raises Target Price to $81 From $71

THOMSON REUTERS
·
09 Jan

MoonLake's Three New Trials Will Expand Sonelokimab's Potential, Wedbush Says

MT Newswires Live
·
09 Jan

MoonLake Immunotherapeutics Starts Three New Clinical Trials Evaluating Sonelokimab in Inflammatory Diseases

MT Newswires Live
·
09 Jan

BRIEF-Moonlake Initiates Three New Clinical Trials And Expands Portfolio Of Indications For The Nanobody Sonelokimab

Reuters
·
08 Jan

MoonLake Immunotherapeutics - Phase 2 and 3 Data Read-Outs Expected in 2025 and 2026

THOMSON REUTERS
·
08 Jan